Reumatoloxía

2007

1. Adipokines as emerging mediators of immune response and inflammation

   Nature Clinical Practice Rheumatology, Vol. 3, Núm. 12, pp. 716-724

2. All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists

   Annals of the Rheumatic Diseases, Vol. 66, Núm. 7, pp. 880-885

3. An SNP in the 5′-UTR of GDF5 is associated with osteoarthritis susceptibility in Europeans and with in vivo differences in allelic expression in articular cartilage

   Human Molecular Genetics, Vol. 16, Núm. 18, pp. 2226-2232

4. Bias in association studies of systemic lupus erythematosus susceptibility due to geographical variation in the frequency of a programmed cell death 1 polymorphism across Europe

   Genes and Immunity, Vol. 8, Núm. 2, pp. 138-146

5. Cancer in Biopsy-Proven Giant Cell Arteritis. A Population-Based Study

   Seminars in Arthritis and Rheumatism, Vol. 37, Núm. 3, pp. 156-163

6. Cell death and apoptosis in ostearthritic cartilage

   Current Drug Targets, Vol. 8, Núm. 2, pp. 333-345

7. Chapter 13 Henoch-Schönlein Purpura

   Handbook of Systemic Autoimmune Diseases, Vol. 7, pp. 241-255

8. Common Variable Immunodeficiency in Systemic Lupus Erythematosus

   Seminars in Arthritis and Rheumatism, Vol. 36, Núm. 4, pp. 238-245

9. Consensus statement on the use of rituximab in patients with rheumatoid arthritis

   Annals of the Rheumatic Diseases, Vol. 66, Núm. 2, pp. 143-150

10. Contribution of MHC class I region to genetic susceptibility for giant cell arteritis

    Rheumatology, Vol. 46, Núm. 3, pp. 431-434

11. Disease pattern of spondyloarthropathies in Spain: Description of the first national registry (REGISPONSER) - Extended report

    Rheumatology, Vol. 46, Núm. 8, pp. 1309-1315

12. Endothelial dysfunction in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors

    Arthritis Care and Research, Vol. 57, Núm. 2, pp. 287-293

13. Evidence-based review of biologic markers as indicators of disease progression and remission in rheumatoid arthritis

    Rheumatology International, Vol. 27, Núm. 9, pp. 793-806

14. Evidencia de mecanismos inflamatorios en la osteoartritis

    Reumatologia Clinica, Vol. 3, Núm. EXTRA 3, pp. 23-27

15. Further evidence of the role of frizzled-related protein gene polymorphisms in osteoarthritis

    Annals of the Rheumatic Diseases, Vol. 66, Núm. 8, pp. 1052-1055

16. Genética en la osteoartritis

    Reumatologia Clinica, Vol. 3, Núm. EXTRA 3, pp. 13-18

17. Giant cell arteritis in northwestern Spain: A 25-year epidemiologic study

    Medicine, Vol. 86, Núm. 2, pp. 61-68

18. Glucosamine sulfate in the treatment of knee osteoarthritis symptoms: A randomized, double-blind, placebo-controlled study using acetaminophen as a side comparator

    Arthritis and Rheumatism, Vol. 56, Núm. 2, pp. 555-567

19. HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis

    Arthritis Care and Research, Vol. 57, Núm. 1, pp. 125-132

20. High prevalence of subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors

    Arthritis Care and Research, Vol. 57, Núm. 6, pp. 1074-1080